Gilead Sciences Inc. (GILD) News

Gilead Sciences Inc. (GILD): $72.50

0.40 (+0.55%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

B

Add GILD to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#8 of 360

in industry

Filter GILD News Items

GILD News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

GILD News Highlights

  • GILD's 30 day story count now stands at 22.
  • Over the past 20 days, the trend for GILD's stories per day has been choppy and unclear. It has oscillated between 1 and 5.
  • DRUG, PRE and CE are the most mentioned tickers in articles about GILD.

Latest GILD News From Around the Web

Below are the latest news stories about GILEAD SCIENCES INC that investors may wish to consider to help them evaluate GILD as an investment opportunity.

The 500 Top Stocks to Buy for 2024, Ranked by AI

These are the very best stocks to buy for 2024 for any investor, according to Tom Yeung's MarketMasterAI system.

Thomas Yeung on InvestorPlace | December 29, 2023

Here's Why Gilead Sciences (NASDAQ:GILD) Can Manage Its Debt Responsibly

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Yahoo | December 28, 2023

The 30 Happiest Cities in America in 2023

In this article, we will take a look at the 30 happiest cities in America in 2023. If you want to skip our discussion on the impact of residence on well-being, you can go directly to The 5 Happiest Cities in America in 2023. Despite the common belief that money can’t buy happiness, one cannot deny […]

Yahoo | December 28, 2023

12 Best Stocks to Buy for an 18 Year Old

In this article, we discuss the 12 best stocks to buy for an 18 year old. If you want to skip our detailed analysis of these stocks, go directly to 5 Best Stocks to Buy for an 18 Year Old. It is an exciting time to be involved in trading stocks. The Federal Reserve in […]

Yahoo | December 28, 2023

A Tale of Two Pharmas: Can Obesity Firms Continue Their Outperformance in 2024?

In pharma, a company can take a larger slice of the healthcare pie than peers, but it is still constrained by the size of the pie.

Yahoo | December 27, 2023

Should You Be Adding Gilead Sciences (NASDAQ:GILD) To Your Watchlist Today?

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...

Yahoo | December 23, 2023

Why Is Hookipa Pharma (HOOK) Stock Up 81% Today?

Hookipa Pharma stock is rising higher on Thursday as investors react to a purchase agreement for 15 million shares of HOOK.

William White on InvestorPlace | December 21, 2023

3 Biotech Stocks to Buy in the TradeSmith ‘Green Zone’

It's now time to take a look at these three biotech stocks to buy, as each one is currently within TradeSmith's "Green Zone."

TradeSmith Research Staff on InvestorPlace | December 21, 2023

U.S. FDA Approves Label Update for Kite’s Yescarta® CAR T-Cell Therapy to Include Overall Survival Data

SANTA MONICA, Calif., December 21, 2023--Kite, a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug Administration (FDA) has approved a label update for Yescarta® (axicabtagene ciloleucel) to include the overall survival (OS) primary analysis from the landmark Phase 3 ZUMA-7 study showing a statistically significant improvement for Yescarta in OS versus standard of care (SOC) as second-line treatment with curative intent for patients with relapsed or refractory large B-ce

Yahoo | December 21, 2023

Gilead Sciences to Present at Upcoming Investor Conference

FOSTER CITY, Calif., December 21, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conference:

Yahoo | December 21, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!